Form 4: Ultragenyx CEO Emil Kakkis Receives Equity Grant

Ultragenyx Pharmaceutical CEO Emil Kakkis was granted 76,745 restricted stock units and 132,693 stock options as part of the company's 2023 incentive plan.

Summary

• Emil Kakkis, President and CEO of Ultragenyx Pharmaceutical, received an equity grant on April 16, 2026.
• The grant includes 76,745 Restricted Stock Units (RSUs) vesting over four years.
• The grant includes 132,693 stock options with an exercise price of $24.52, expiring in 2036.
• The reporting person also contributed 400,000 shares into two Grantor Retained Annuity Trusts (GRATs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation and internal trust management, which is neutral for the stock price.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Continued leadership stability with the CEO maintaining significant direct and indirect ownership stakes.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Vesting conditions for RSUs and options are subject to continued service and performance criteria.
• Market volatility affecting the value of the granted options and underlying common stock.

Future Outlook

The equity grants are subject to standard multi-year vesting schedules, indicating a long-term retention strategy for the CEO.

Management Comments

• The grants are issued under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure alignment with long-term drug development milestones and shareholder interests.

Comparison to Industry Standards

• The use of a four-year vesting schedule for RSUs is consistent with standard corporate governance practices in the U.S. biotech industry.
• The inclusion of both RSUs and stock options is a common compensation structure for CEOs in mid-cap pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution from the new equity issuance.

Next Steps

• Vesting of 1/4th of the RSUs on the first anniversary of the grant date.
• Vesting of 1/4th of the stock options on the first anniversary of the grant date.

Key Dates

Keywords

Ultragenyx, RARE, Emil Kakkis, Form 4, Insider Trading, Equity Compensation, Biotech